YOUR SEARCH FOR Text 28 RESULTS
11 of Total
Contact Us | Incyte.com.com
… medinfocanada@incyte.com Asia Japan 0120094139 jpmedinfo@incyte.com Europe +800 …
12 of Total
Financials | Incyte
… 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 …
13 of Total
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance
… $ 59,163 $ 43,874 35 % $ 206,997 $ 150,991 37 % Non-GAAP cost of product revenues … general and administrative expenses $1,050 - $1,150 million Non-GAAP Selling, general and …
14 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… revenues $ 43,874 $ 36,323 21% $ 150,991 $ 131,328 15% Non-GAAP cost of … amortization) 43,874 36,323 150,991 131,328 Research and development …
15 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Product revenues, net $ 663,851 $ 575,150 $ 1,269,672 $ 1,079,961 Product royalty … Other intangible assets, net 139,987 150,755 Goodwill 155,593 155,593 …
16 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | Incyte
… and contract revenues 45,000 18,000 150 % 150 % 50,000 43,000 16 % 16 % Total …
17 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… — 2,903 — % (1,025 ) 2,045 (150 %) 1 Non-GAAP cost of product revenues …
18 of Total
Understanding Hidradenitis Suppurativa (HS) | Incyte Stories
… must continue to Solve On . for the more than 150,000 patients in the U.S. who navigate the …
19 of Total
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Other intangible assets, net 145,371 150,755 Goodwill 155,593 155,593 Deferred …
20 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
Press Release View all news Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&